Wed Sep 3 00:36:36 SGT 2014  
SINGAPORE
SEXUALHEALTH™
    Genital Warts
SINGAPORE SEXUALHEALTH™
Within 3 days after unprotected sex, stop HIV infection with Post-Exposure Prophylaxis treatment 10 days after unprotected sex, detect HIV infection with the DNA test 28 days after unprotected sex, accurately detect HIV infection with the 20 minute rapid test
Full & comprehensive sexually transmitted disease testing
Males: do not urinate for at least 4 hours before arriving
Females: testing is more accurate when you are not menstruating

Genital Warts | SINGAPORE SEXUALHEALTH™

Summary

Genital Warts | SINGAPORE SEXUALHEALTH™ @singaporesexualhealth_com: Genital warts, Singapore. Private & confidential service.

Advertisement: Come to sunny Singapore to have your testing and treatment. Singapore Ministry of Health registered general practice (GP) clinic:
SHIM CLINIC
SINGAPORE SEXUALHEALTH™
168 Bedok South Avenue 3 #01-473
Singapore 460168
Tel: (+65) 6446 7446
Fax: (+65) 6449 7446
24hr Answering Tel: (+65) 6333 5550
Web: Genital Warts | SINGAPORE SEXUALHEALTH™
Opening Hours
Monday to Friday: 9 am to 3 pm, 7 pm to 11 pm
Saturday & Sunday: 7 pm to 11 pm
Public Holidays: Closed
Last registration: one hour before closing time.
Walk-in clinic. Appointments not required.
Bring NRIC, Work Pass or Passport for registration.

Description

Table of Contents

Genital warts: penile warts / vaginal warts / anal warts / anogenital warts / venereal warts / condyloma / condylomata acuminata / "cauliflower" sex disease.

References

Warts - on male sex organ Genital warts appear within 3 months after sexual contact with an infected person.

Genital warts:

  • are usually soft, pink cauliflower-like growths or flesh-coloured bumps on the sex organs
  • may also be hard and smooth
  • occur alone or in groups
  • tend to recur after treatment
  • increase the risk of cervical cancer in women.


Warts - on female sex organ An infected woman may infect her newborn during childbirth.

A person with genital warts can infect others through sexual contact.



Genital warts treatment / HPV treatment

HPV / human papillomavirus.

  • 120 known human papillomavirus (HPV)
  • 51 HPV types, and 3 subtypes are genital HPV as they infect the genital mucosa.
  • 31 genital HPV types are low risk
  • 6 genital HPV types are intermediate risk
  • 17 genital HPV types are high risk
They cause Cervical cancer HPV vaccine (previously known as cervical cancer vaccine) types:
  • Gardasil® [HPV (Human Papillomavirus) Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant]
  • Cervarix® [HPV (Human Papillomavirus) Bivalent (Types 16 and 18) Vaccine, Recombinant]
  • V503 [HPV (Human Papillomavirus) Nonavalent (Types 6, 11, 16, 18, 31, 33, 45, 52, and 58) Vaccine, Recombinant]
References Gardasil® [HPV (Human Papillomavirus) Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] References Cervarix® [HPV (Human Papillomavirus) Bivalent (Types 16 and 18) Vaccine, Recombinant] References V503 [HPV (Human Papillomavirus) Nonavalent (Types 6, 11, 16, 18, 31, 33, 45, 52, and 58) Vaccine, Recombinant] - to be released in 2013 STD vaccine / hepatitis vaccine shot/jab/injection to prevent some STDs

Vaccine Against Disease Age D
o
s
e
s
Dose schedule Price
per
dose
(SG$)
Havrix™ 1440 Adult Hepatitis A virus Hepatitis A ≥19y 2 m 0 & 6-12 $90/=
Twinrix® Hepatitis A virus
Hepatitis B virus
Hepatitis A
Hepatitis B
1-15y 2 m 0, 6-12 $120/=
≥16y 3 m 0, 1, 6
4 d 0, 7, 21 & m 12
Inactivated / Fractional / Protein / Subunit / Recombinant
Engerix™-B 20 μg Hepatitis B virus Hepatitis B 11-15y 2 m 0, & 6 $50/=
≥20y 3 m 0, 1, & 6
4 m 0, 1, 2, & 12 or
d 0, 7, 21 & m 12
Gardasil® HPV
types 6, 11, 16, & 18
Genital warts
Cervical cancer
9-26y 3 m 0, 2, & 6 or
m 0, 1, & 4
$195/=
Cervarix® HPV
types 16, & 18
(31, 33, & 45)
10-25y 3 m 0, 1, & 6
m 0, 1, & 5
m 0, 2½, 12
$195/=
V503 HPV
types 6, 11, 16, 18,
31, 33, 45,
52, & 58
3 m 0, 2, & 6 or
m 0, 1, & 4
$???/=

HPV test for men/women.

  • Digene® High-Risk HPV DNA Test
  • Digene® HPV DNA Test
  • Digene® HPV Genotyping PS Test
  • Hybribio®
    • HPV GenoArray Test Kit
    • Detects 15 high-risk HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, and 68. And 6 low-risk HPV types: 6, 11, 42, 43, 44, CP8304
    • Able to differentiate which types are positive.
    • May be available in Singapore soon.
  • Cobas® HPV Test
    • Cobas® HPV Test
    • Detects 14 high-risk HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68
    • The test specifically identifies (types) HPV 16 and HPV 18, while concurrently detecting the rest of the high risk types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68)
    • Cost is SG$200/=
  • LINEAR ARRAY® HPV Genotyping Test
    • LINEAR ARRAY® HPV Genotyping Test
    • Identifies 37 high-risk HPV genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 73 (MM9), 82 (MM4) low-risk HPV genotypes 6, 11, 26, 40, 42, 53, 54, 55, 61, 62, 64, 67, 69, 70, 71, 72, 81, 83 (MM7), 84 (MM8), IS39, and CP6108
  • INNO-LiPA HPV Genotyping Extra
    • INNO-LiPA HPV Genotyping Extra
    • Identifies 15 high-risk HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82) 3 probable high-risk HPV genotypes (26, 53, 66) 7 low-risk HPV genotypes (6, 11, 40, 43, 44, 54, 70) and some additional types (69, 71, 74).
  • PapilloCheck®
    • PapilloCheck®
    • Identifies 24 hiv-risk HPV types 16 18 31 33 35 39 45 51 52 53 56 58 59 66 68 70 73 82 and low-risk HPV types 6 11 40 42 43 44

Sexual risk (of HIV/STD/pregnancy), and what you can do before and after exposure.

Timeline Event / Available resources
HIV STD Pregnancy
Before exposure
Abstain from sex, Be faithful, or Condom use
Circumcision (males only)
Contraception
(females only)
HIV PrEP (pre-exposure prophylaxis) STD vaccine:
- Hepatitis vaccine
- HPV vaccine
STD / HIV exposure
Unsafe sex / unprotected sex:
No condom / Condom broke / Condom slip
0-72 hours HIV prevention
HIV PEP (post-exposure prophylaxis) treatment
- Stop HIV infection after exposure.
STD testing
If STD symptoms appear, then do STD treatment.
- Males: Do not urinate for at least 4 hours before arriving.
- Females: testing is more accurate when you are not menstruating.
Emergency contraception
(females only)
2 weeks HIV DNA PCR test
1 month 20 minute SD Bioline HIV Ag/Ab Combo HIV rapid test:
- Fingerprick blood sampling.
3 months 20 minute OraQuick® HIV rapid test:
- Oral saliva or
- Fingerprick blood sampling.
Full & comprehensive STD testing
- Males: Do not urinate for at least 4 hours before arriving.
- Females: testing is more accurate when you are not menstruating.

References


Latest News

Vulvar vitiligo-like depigmentation and multiple halos of hypomelanosis at the trunk following treatment with imiquimod 5% cream for vulvar condylomata: casual or related events?
Tue, 02 Sep 2014 15:13:26 +0100 | Anais Brasileiros de Dermatologia
A 25-year-old Caucasian female with multiple genital warts involving the vulvar area was treated with imiquimod 5% cream. During follow-up the patient developed areas of hypopigmentation at the site of application of imiquimod cream and areas of hypomelanosis around multiple preexisting nevi of the trunk. At 18 months follow-up genital depigmentation persisted and halo nevi of the trunk were still present. Different mechanisms of imiquimod-induced depigmentation have been reported. Halo nevi are considered expression of an autoimmune response. In the case presented here, it might be conceivable that both vitiligo-like depigmentation at the site of application and halo of hypomelanosis around melanocytic nevi have been induced by the same immunologic mechanism elicited by topical applicatio...

Estimation of Geographic Variation in Human Papillomavirus Vaccine Uptake in Men and Women: An Online Survey Using Facebook Recruitment
Mon, 01 Sep 2014 00:00:00 +0100 | Journal of Medical Internet Research
Conclusions: This study shows that recruiting a representative sample of young men and women based on county and postal code location to complete a survey on HPV vaccination uptake via the Internet is a cost-effective and feasible strategy. This study also highlights the need for local estimates to assess the variation in HPV vaccine uptake, as these estimates differ considerably from those obtained using survey data that are aggregated to the state or federal level. (Source: Journal of Medical Internet Research)

The tahoe study: bias in the interpretation of papanicolaou test results when human papillomavirus status is known.
Mon, 01 Sep 2014 00:00:00 +0100 | Archives of Pathology and Laboratory Medicine
Conclusions.-Knowledge of positive HPV status biases morphologic Pap test result interpretation. If the HPV status is positive, observers are more likely to report a Pap test result as abnormal across all categories of ECAs.

Cervical screening rates for women vaccinated against human papillomavirus.
Sat, 30 Aug 2014 11:50:46 +0100 | Med J Aust
CONCLUSIONS: Despite education messages provided to young women, our results suggest that vaccinated women are being screened at lower rates than unvaccinated women in Australia. While some degree of undermatching of women in the study may have occurred, this cannot wholly explain our findings. Effective implementation of Individual Healthcare Identifiers to health records, including registry records, is needed to prevent potential undermatching of individuals in future linkage studies. In the meantime, efforts to increase participation in cervical screening by vaccinated women are needed.

Update on Opportunistic Infections in the Era of Effective Antiretroviral Therapy
Fri, 29 Aug 2014 21:48:20 +0100 | Infectious Diseases Clinics of North America
Despite enormous improvements in effectiveness of treatment for HIV infection, opportunistic infections continue to occur in those who have not yet been diagnosed with HIV and in those who are not receiving antiretroviral therapy. This review focuses on tuberculosis and cryptococcal infections, the most common opportunistic infections (OIs) in patients living with human immunodeficiency virus infection around the world, as well as on new developments in progressive multifocal leukoencephalopathy and pneumocystis pneumonia. In the sections on these conditions, updates on diagnosis, treatment, and complications, as well as information on when to start antiretroviral therapy is provided. The article concludes with a discussion of new data on 2 vaccine-preventable OIs, human papillomavirus and...

RECOMMENDATIONS AND REPORTS: Human Papillomavirus Vaccination: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
Fri, 29 Aug 2014 03:41:36 +0100 | CDC Morbidity and Mortality Weekly Report
(Source: CDC Morbidity and Mortality Weekly Report)

Coblation plus photodynamic therapy (PDT) for the treatment of juvenile onset laryngeal papillomatosis: case reports
Fri, 29 Aug 2014 00:00:00 +0100 | World Journal of Surgical Oncology
Conclusion:

Human Papillomavirus Vaccination.
Fri, 29 Aug 2014 00:00:00 +0100 | MMWR Recomm Rep
This report summarizes the epidemiology of human papillomavirus (HPV) and associated diseases, describes the licensed HPV vaccines, provides updated data from clinical trials and postlicensure safety studies, and compiles recommendations from CDC's Advisory Committee on Immunization Practices (ACIP) for use of HPV vaccines. Persistent infection with oncogenic HPV types can cause cervical cancer in women as well as other anogenital and oropharyngeal cancers in women and men. HPV also causes genital warts. Two HPV vaccines are licensed in the United States. Both are composed of type-specific HPV L1 protein, the major capsid protein of HPV. Expression of the L1 protein using recombinant DNA technology produces noninfectious virus-like particles (VLPs). Quadrivalent HPV vaccine (HPV4) contains...

miR-135a leads to cervical cancer cell transformation through regulation of {beta}-catenin via a SIAH1-dependent ubiquitin proteosomal pathway
Wed, 27 Aug 2014 00:00:00 +0100 | Carcinogenesis
In this study, we compared the expression of miR-135a in laser capture microdissected cervical specimens and confirmed overexpression of the miRNA in malignant cervical squamous cell carcinoma compared with precancerous lesions. Transient force-expression of miR-135a induced growth in low-density culture, anchorage-independent growth, proliferation and invasion of a HPV-16 E6/E7-immortalized cervical epithelial cell line, NC104-E6/E7. The observed effects were due to the inhibitory action of miR-135a on its direct target seven in absentia homolog 1 (SIAH1) leading to upregulation of β-catenin/T cell factor signaling. miR-135a force-expression enhanced the growth of HeLa- and NC104-E6/E7-derived tumor in vivo. The effect of miR-135a could be partially nullified by SIAH1 force-expressio...

Detection Of Human Papillomavirus In The Oral Cavities Of Persons With Fanconi Anemia
Wed, 27 Aug 2014 00:00:00 +0100 | Oral Diseases
ConclusionsPrevalence of oral human papillomavirus infection in persons with Fanconi Anemia was comparable to estimates from other studies in the general population. However, in contrast to previous studies, we did not identify human papillomavirus type 16 (the type found in most human papillomavirusā€related head and neck cancers) in any participants.This article is protected by copyright. All rights reserved. (Source: Oral Diseases)